Catalyst Pharmaceuticals Inc (CPRX)
Solvency ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 1.17 | 1.17 | 1.16 | 1.15 | 1.22 | 1.19 | 1.18 | 1.22 | 1.25 | 1.23 | 1.11 | 1.12 | 1.15 | 1.12 | 1.11 | 1.10 | 1.13 | 1.12 | 1.18 | 1.18 |
Catalyst Pharmaceuticals Inc has consistently maintained a strong solvency position as evidenced by its consistently low debt-related ratios. The debt-to-assets ratio, which measures the extent to which the company's assets are financed by debt, has consistently been reported at 0.00, indicating that the company has no debt relative to its total assets.
Similarly, the debt-to-capital ratio, which provides insights into the proportion of a company's capital that is debt-financed, has also remained at 0.00 across all reported periods. This suggests that the company has not utilized debt significantly to fund its operations or investments.
Furthermore, the debt-to-equity ratio, a measure of the company's financial leverage and risk, has been consistently reported at 0.00. This indicates that Catalyst Pharmaceuticals Inc has not relied on debt financing to support its equity position, reflecting a conservative financial structure.
The financial leverage ratio, which considers the company's total assets in relation to shareholder equity, has shown some fluctuations over the periods analyzed. Despite these fluctuations, the ratio has generally remained within a reasonable range, indicating that the company's capital structure has not posed significant risks to its solvency.
Overall, based on the solvency ratios analyzed, Catalyst Pharmaceuticals Inc appears to have a strong financial position with minimal reliance on debt financing, signaling a stable and sustainable financial structure.
Coverage ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | — | 66.60 | 44.74 | 45.85 | 23.48 | 15.14 | 24.10 | 19.59 | 24.40 | 63.33 | 173.91 | 642.42 | — | 142.99 | 136.47 | 120.35 | 61.51 | 55.41 | 37.94 | 27.49 |
Interest coverage ratio measures a company's ability to pay interest expenses on its outstanding debt. A higher interest coverage ratio indicates that the company is more capable of meeting its interest obligations.
Analyzing the interest coverage ratio of Catalyst Pharmaceuticals Inc over the past few years, we observed a fluctuating trend. The ratio increased from 27.49 on March 31, 2020, to a peak of 642.42 on March 31, 2022, indicating a significant improvement in the company's ability to cover its interest expenses.
However, the ratio declined thereafter, with a notable drop to 15.14 on September 30, 2023. This decline raises concerns about the company's ability to service its interest payments efficiently.
Subsequently, the interest coverage ratio recovered slightly, reaching 66.60 on September 30, 2024. It is worth noting that for December 31, 2021, and December 31, 2024, the interest coverage data is not available (indicated by "—"), which could be due to missing financial information.
Overall, the fluctuating trend in Catalyst Pharmaceuticals Inc's interest coverage ratio highlights the company's changing ability to cover its interest obligations and suggests the need for further examination of its financial health and debt management strategies.